Trovagene (TROV+8%) gets a pop today after granting Novartis (NVS) subsidiary Genoptix licensing rights to incorporate its nucleophosmin protein, NPM1, into research and clinical testing services for acute myelogenous leukemia. Trovagene holds an exclusive patent on the protein. Terms of the agreement include upfront fees and royalty payments. Additional financial terms were not disclosed. Additionally, Roth Capital initiates the shares with a Buy and a price target of $11 a share.